Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
2.820
-0.050 (-1.74%)
At close: Jun 26, 2026, 4:00 PM EDT
2.800
-0.020 (-0.71%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Altimmune Employees
Altimmune had 57 employees as of December 31, 2025. The number of employees decreased by 2 or -3.39% compared to the previous year.
Employees
57
Change (1Y)
-2
Growth (1Y)
-3.39%
Revenue / Employee
$632
Profits / Employee
-$1,597,912
Market Cap
548.42M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57 | -2 | -3.39% |
| Dec 31, 2024 | 59 | 0 | - |
| Dec 31, 2023 | 59 | 7 | 13.46% |
| Dec 31, 2022 | 52 | 5 | 10.64% |
| Dec 31, 2021 | 47 | 4 | 9.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Gyre Therapeutics | 625 |
| 4D Molecular Therapeutics | 196 |
| Prime Medicine | 146 |
| BridgeBio Oncology Therapeutics | 106 |
| Tectonic Therapeutic | 60 |
| Crescent Biopharma | 55 |
| Achieve Life Sciences | 28 |
ALT News
- 5 days ago - Altimmune initiated with an Outperform at Leerink - TheFly
- 5 days ago - Altimmune initiated with an Outperform at Leerink - TheFly
- 17 days ago - Altimmune Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 23 days ago - Altimmune Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide - TheFly
- 4 weeks ago - Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 - GlobeNewsWire
- 4 weeks ago - Altimmune to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 - GlobeNewsWire